Brief: Secarna Pharmaceuticals And Achilles Therapeutics Sign Research Agreement To Develop Optimized T Cell Therapies

Achilles Therapeutics

10/11/2021 13:01

Nov 10 (Reuters) - ACHILLES THERAPEUTICS PLC  698y.F :
    * SECARNA PHARMACEUTICALS AND ACHILLES THERAPEUTICS SIGN
RESEARCH,
OPTION AND LICENSE AGREEMENT TO DEVELOP OPTIMIZED T CELL
THERAPIES
    * UNDER TERMS OF AGREEMENT, SECARNA WILL RECEIVE AN
UNDISCLOSED
UPFRONT PAYMENT, A TARGET-BASED TECHNOLOGY ACCESS FEE AS WELL AS
OPTION EXERCISE FEES
    * SECARNA IS ALSO ELIGIBLE TO RECEIVE DEVELOPMENT AND
COMMERCIAL
MILESTONE PAYMENTS AS WELL AS TIERED ROYALTIES ON NET SALES OF
PERSONALIZED T CELL THERAPIES DEVELOPED AND COMMERCIALIZED UNDER
THIS COLLABORATION

Source text for Eikon:  ID:nEQ1JMc0la 
Further company coverage:  698y.F 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))